Brand name companies oppose review of drug industry. (Health).OTTAWA -- The Canadian Pharmaceutical Manufactures Association takes issue with the proposals in the Romanow Commission on the Future of Health Care that calls for an immediate "review of the pharmaceutical industry practises related to patent protection." The CPMA CPMA Canadian Produce Marketing Association CPMA Challenge Promode Arena (Quake 3 modification) CPMA Color Pigments Manufacturers Association, Inc. , representing the large brand-name companies, claims that this will retard research and development in Canada. President Murray J. Elston says "Commissioner Romanow's recommendations will increase bureaucracy in the health care system in areas where provinces already have jurisdiction". The Canadian Generic Pharmaceutical Association supports the Romanow recommendations. President Jim Keon says: "Abuse of drug patent laws that delay Canadians' access to lower-cost generic drugs generic drug, a drug sold or prescribed under the nonproprietary name of its active ingredients or under a generally descriptive name rather than under a brand or trade name. even after original 20-year patents expire is too expensive to be allowed to continue." He adds that the regulations allow brand-name drug Noun 1. brand-name drug - a drug that has a trade name and is protected by a patent (can be produced and sold only by the company holding the patent) proprietary drug drug - a substance that is used as a medicine or narcotic companies to stop Health Canada Health Canada (French: Santé Canada) is the department of the government of Canada with responsibility for national public health. Health Canada's goal is to improve Canadian life by improving Canadian longevity, lifestyle and use of public healthcare. approval of generic drugs simply by alleging patent infringement patent infringement n. the manufacture and/or use of an invention or improvement for which someone else owns a patent issued by the government, without obtaining permission of the owner of the patent by contract, license or waiver. . The automatic 24-month stay under the Regulations means that Health Canada cannot approve a generic drug until any claim of alleged patent infringement is decided in court. "Brand name drug companies often find it more lucrative to litigate than to innovate." The CPMA "believes the best possible health outcomes for patients should be the first priority, this is certainly not evident in this report." The Romanow report emphasizes cost containment cost containment, n the features of a dental benefits program or of the administration of the program designed to reduce or eliminate certain charges to the plan. and undervalues research. 613-236-0455 |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion